Soaring Demand Set to Propel Thrombophilia Market to $24.57 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Thrombophilia Market Through 2025?
The scale of the thrombophilia market has seen significant expansion lately. The market's estimated value is set to rise from $17.03 billion in 2024 to $18.18 billion in 2025, representing a compound annual growth rate (CAGR) of 6.7%. The noteworthy expansion during the historical period is due to increased consciousness, advancements in research and development of anticoagulant therapies, an aging demographic, advances in genetic research, and a heightened occurrence of thrombotic disorders.

What's the Projected Size of the Global Thrombophilia Market by 2029?
In the forthcoming years, the thrombophilia market is projected to experience robust growth, expanding to "$24.57 billion in 2029 with a compound annual growth rate (CAGR) of 7.8%. The increasing growth during the forecast period can be credited to factors like personalized medicine, the arrival of groundbreaking therapies, the introduction of artificial intelligence, healthcare regulations and policies, and enhanced patient knowledge and empowerment. Significant trends expected during the forecast period encompass technological innovations, the enlargement of telemedicine's role, escalating incidence rates, advancements in biopharmaceuticals, and cooperative research programs.

View the full report here:
https://www.thebusinessresearchcompany.com/report/thrombophilia-global-market-report

Top Growth Drivers in the Thrombophilia Industry: What's Accelerating the Market?
The anticipated surge in the population of the elderly is believed to stimulate the thrombophilia market's expansion. The term 'elderly population' pertains to those who are 65 years old and above, with the dependent population ratio calculated by the total number of elders and youth relative to the entire population. Various thrombophilic risk elements are fairly prevalent among older adults, enabling the detection of a demographic with high risk for negative health results. Consequently, an escalated elderly population volume will fuel the market due to the heightened demand for thrombophilia medication. For example, data from America's Health Rankings-an organization based in the US that evaluates health outcomes-revealed that in 2022, over 56 million adults aged 65+ made up roughly 16.9% of the entire US populace. By 2030, the elderly population is estimated to exceed 73.1 million. As such, the rising elderly population is facilitating the thrombophilia market's growth.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9439&type=smp

What Are the Key Trends Driving Thrombophilia Market Growth?
The thrombophilia market is witnessing an upward trend, driven by advancements in technology. The major players in the market are focused on the creation of new technologies to maintain their market standings. For example, in May 2023, the University of California, San Diego, unveiled an innovative technology called Eloctate, envisioned to revolutionize hemophilia treatment. This pioneering technique uses an unique fusion protein that drastically improves the half-life and stability of coagulation factors within the blood. The goal is to integrate this technology with current therapies to develop long-lasting drugs that necessitate less frequent doses, thereby positively impacting patient compliance and enhancing their quality of life.

What Are the Main Segments in the Thrombophilia Market?
The thrombophilia market covered in this report is segmented -

1) By Type: Factor V Leiden, Prothrombin 20210, Antiphospholipid Syndrome, Other Type
2) By Drugs: Heparin, Warfarin, Other Drugs
3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration
4) By End-Users: Hospitals, Homecare, Specialty Centers, Other End Users

Subsegments:
1) By Factor V Leiden: Genetic Testing, Anticoagulant Therapy
2) By Prothrombin 20210: Genetic Testing, Anticoagulant Therapy
3) By Antiphospholipid Syndrome: Antiphospholipid Antibody Testing, Anticoagulant Therapy
4) By Other Types: Protein C Deficiency, Protein S Deficiency, Antithrombin III Deficiency, Other Genetic Conditions

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=9439&type=smp

Which Top Companies are Driving Growth in the Thrombophilia Market?
Major companies operating in the thrombophilia market include Pfizer Inc., F. Hoffmann-La Roche Limited, Changzhaou Qianhong Bio-pharma Co. Limited, Fresenius Kabi AG, Hebei Changshan Biochemical Pharmaceutical Co. Limited, Hikma Pharmaceuticals PLC., Novartis AG, Shanghai Fosun Pharmaceutical (Group) Co. Ltd., Shenzhen Hepalink Pharmaceutical Group Co. Limited, Teva Pharmaceutical Industries Limited, Yino Pharma Limited, Sanofi SA, Eisai Co. Limited, Boehringer Ingelheim GmbH, Instrumentation Laboratory SpA, Johnson & Johnson, Laurus Lab, Bristol-Myers Squibb, Roche, Abbott, C. H. Boehringer Sohn, Portola Pharmaceuticals, Daiichi Sankyo, Bayer Group, GlaxoSmithKline plc, CSL Behring

Which Regions Will Dominate the Thrombophilia Market Through 2029?
North America was the largest region in the thrombophilia market in 2024. The regions covered in the thrombophilia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9439

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.